A retrospective cohort study of 124 men with biopsy Gleason 6 prostate cancer found that elevated PSA density and perineural ...
A phase 3 PROTEUS substudy published in European Urology reports that perioperative apalutamide plus hormone therapy around ...
What’s New On Radiotherapy of Prostate Cancer in 2026? / OncoDaily RT, prostate cancer, prostate cancer radiotherapy, ...
Proud to Share New PROTEUS Findings on Perioperative Treatment in High-Risk Prostate Cancer / A Douglas Laird, ADT, Alberto ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
The retailer, which has just under 500 stores across the country, announced earlier this year that it had completed the ...
Darolutamide plus ADT and radiotherapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone.
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...
Clarity Pharmaceuticals announced that the registrational Phase III CLARIFY trial (NCT06056830) has dosed the planned target of 383 participants in the study. CLARIFY (Positron Emission Tomography ...
Diagnosed in December 2022, medical professional Shailesh Pathak opted for non-surgical treatment over prostate removal due ...
Perioperative apalutamide plus ADT and surgery lowered risk of recurrence or death by 62% in high-risk localized or locally advanced prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results